AU2006283703A1 - Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof - Google Patents
Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof Download PDFInfo
- Publication number
- AU2006283703A1 AU2006283703A1 AU2006283703A AU2006283703A AU2006283703A1 AU 2006283703 A1 AU2006283703 A1 AU 2006283703A1 AU 2006283703 A AU2006283703 A AU 2006283703A AU 2006283703 A AU2006283703 A AU 2006283703A AU 2006283703 A1 AU2006283703 A1 AU 2006283703A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- formula
- compound
- short
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 heteroaryl compound Chemical class 0.000 title claims description 268
- 239000003326 hypnotic agent Substances 0.000 title claims description 129
- 125000003118 aryl group Chemical group 0.000 title claims description 42
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- 239000003826 tablet Substances 0.000 claims description 78
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 73
- 239000008188 pellet Substances 0.000 claims description 71
- 229960001475 zolpidem Drugs 0.000 claims description 66
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 230000003111 delayed effect Effects 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 239000010410 layer Substances 0.000 claims description 36
- 208000019116 sleep disease Diseases 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 206010022437 insomnia Diseases 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 208000020685 sleep-wake disease Diseases 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 208000020016 psychiatric disease Diseases 0.000 claims description 12
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 11
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 11
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 10
- 239000007950 delayed release tablet Substances 0.000 claims description 10
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 10
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 10
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 7
- 239000011247 coating layer Substances 0.000 claims description 7
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 claims description 7
- 229960001578 eszopiclone Drugs 0.000 claims description 7
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical class COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 7
- 229960000820 zopiclone Drugs 0.000 claims description 7
- 206010027590 Middle insomnia Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 claims description 5
- 102000004300 GABA-A Receptors Human genes 0.000 claims description 5
- 108090000839 GABA-A Receptors Proteins 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 229960003051 brotizolam Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 5
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003386 triazolam Drugs 0.000 claims description 5
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004010 zaleplon Drugs 0.000 claims description 5
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 claims description 4
- CBIAWPMZSFFRGN-UHFFFAOYSA-N Indiplon Chemical compound CC(=O)N(C)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C(=O)C=2SC=CC=2)=C1 CBIAWPMZSFFRGN-UHFFFAOYSA-N 0.000 claims description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 4
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 claims description 4
- 229960004404 etizolam Drugs 0.000 claims description 4
- 229950003867 indiplon Drugs 0.000 claims description 4
- 229960003987 melatonin Drugs 0.000 claims description 4
- 229960001150 ramelteon Drugs 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 102000001419 Melatonin receptor Human genes 0.000 claims description 3
- 108050009605 Melatonin receptor Proteins 0.000 claims description 3
- 239000002974 melatonin derivative Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000002662 enteric coated tablet Substances 0.000 claims 1
- 230000007958 sleep Effects 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
- 239000008187 granular material Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- 125000001544 thienyl group Chemical group 0.000 description 20
- 125000002541 furyl group Chemical group 0.000 description 19
- 125000004076 pyridyl group Chemical group 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 238000000576 coating method Methods 0.000 description 17
- 125000001207 fluorophenyl group Chemical group 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 13
- 238000007906 compression Methods 0.000 description 13
- 230000006835 compression Effects 0.000 description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000008108 microcrystalline cellulose Substances 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 description 11
- 125000004193 piperazinyl group Chemical group 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 10
- 125000003373 pyrazinyl group Chemical group 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical group C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 125000003386 piperidinyl group Chemical group 0.000 description 9
- 230000037322 slow-wave sleep Effects 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229920003134 Eudragit® polymer Polymers 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 125000000068 chlorophenyl group Chemical group 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 125000006332 fluoro benzoyl group Chemical group 0.000 description 8
- 125000004175 fluorobenzyl group Chemical group 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 150000001557 benzodiazepines Chemical class 0.000 description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 230000003860 sleep quality Effects 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 6
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 229920003084 Avicel® PH-102 Polymers 0.000 description 5
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 125000006333 difluoro benzoyl group Chemical group 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 238000005932 reductive alkylation reaction Methods 0.000 description 5
- 201000002859 sleep apnea Diseases 0.000 description 5
- 208000022925 sleep disturbance Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101150104779 HTR2A gene Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 208000006199 Parasomnias Diseases 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000003934 aromatic aldehydes Chemical class 0.000 description 3
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 206010020765 hypersomnia Diseases 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 description 3
- JSCTYNKYJGSRJV-UHFFFAOYSA-N n'-benzyl-n'-[[3-(1h-indol-5-yl)phenyl]methyl]-n,n-dimethylethane-1,2-diamine Chemical compound C=1C=CC(C=2C=C3C=CNC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 JSCTYNKYJGSRJV-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 230000008667 sleep stage Effects 0.000 description 3
- 230000037321 sleepiness Effects 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 229960005111 zolpidem tartrate Drugs 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- QKEKUZYEHOVYSN-UHFFFAOYSA-N 3-(1h-indol-5-yl)benzaldehyde Chemical compound O=CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 QKEKUZYEHOVYSN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- MIYODQRDAPJMKK-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-trityl-1,3-benzoxazol-2-one Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N(C(=O)O2)C(C=3C=CC=CC=3)(C=3C=CC=CC=3)C=3C=CC=CC=3)C2=C1 MIYODQRDAPJMKK-UHFFFAOYSA-N 0.000 description 2
- CRKJYSGULUUTIV-UHFFFAOYSA-N 6-bromo-3-trityl-1,3-benzoxazol-2-one Chemical compound O=C1OC2=CC(Br)=CC=C2N1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CRKJYSGULUUTIV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- KKAXNAVSOBXHTE-UHFFFAOYSA-N boranamine Chemical compound NB KKAXNAVSOBXHTE-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DDNKJFBQMQOIKI-UHFFFAOYSA-N cincreasin Chemical compound BrC1=CC=C2NC(=O)OC2=C1 DDNKJFBQMQOIKI-UHFFFAOYSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 229960005168 croscarmellose Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940057975 ethyl citrate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229950004346 gaboxadol Drugs 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 150000002941 palladium compounds Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000002400 serotonin 2A antagonist Substances 0.000 description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- UBAZQJTUNPKEGK-UHFFFAOYSA-N tert-butyl 5-(4-fluoro-3-formylphenyl)indazole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)N=CC2=CC=1C1=CC=C(F)C(C=O)=C1 UBAZQJTUNPKEGK-UHFFFAOYSA-N 0.000 description 2
- CAQGDWLRIQCXSP-UHFFFAOYSA-N tert-butyl 5-bromoindazole-1-carboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)N=CC2=C1 CAQGDWLRIQCXSP-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JWZQJTGQFHIRFQ-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-6-carboxylic acid Chemical compound O1CCOC2=CC(C(=O)O)=CC=C21 JWZQJTGQFHIRFQ-UHFFFAOYSA-N 0.000 description 1
- XXTXDVUAHROLBN-UHFFFAOYSA-N 2-(trifluoromethoxy)benzamide Chemical compound NC(=O)C1=CC=CC=C1OC(F)(F)F XXTXDVUAHROLBN-UHFFFAOYSA-N 0.000 description 1
- NNEKEQRIVLVCKR-UHFFFAOYSA-N 2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)benzaldehyde Chemical compound O1C(C)(C)C(C)(C)OC1C1=CC=C(C=O)C(F)=C1 NNEKEQRIVLVCKR-UHFFFAOYSA-N 0.000 description 1
- MULLEGQJPXQISM-UHFFFAOYSA-N 2-fluoro-5-(1-tritylbenzotriazol-5-yl)benzaldehyde Chemical compound C1=C(C=O)C(F)=CC=C1C1=CC=C(N(N=N2)C(C=3C=CC=CC=3)(C=3C=CC=CC=3)C=3C=CC=CC=3)C2=C1 MULLEGQJPXQISM-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- BITVLRXIXBFBAR-UHFFFAOYSA-N 2-oxoacetyl fluoride Chemical compound FC(=O)C=O BITVLRXIXBFBAR-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 1
- YFQFIPQQCGDESN-UHFFFAOYSA-N 4-chloro-n-[2-(dimethylamino)ethyl]-n-[[3-(2-oxo-3h-1,3-benzothiazol-6-yl)phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3SC(=O)NC3=CC=2)=CC=1CN(CCN(C)C)C(=O)C1=CC=C(Cl)C=C1 YFQFIPQQCGDESN-UHFFFAOYSA-N 0.000 description 1
- DFSFDJWPILSHHC-UHFFFAOYSA-N 4-chloro-n-[2-(dimethylamino)ethyl]-n-[[3-(2-oxo-3h-1,3-benzoxazol-6-yl)phenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3OC(=O)NC3=CC=2)=CC=1CN(CCN(C)C)C(=O)C1=CC=C(Cl)C=C1 DFSFDJWPILSHHC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HSKVFCUSNYYKBX-UHFFFAOYSA-N 4-fluoro-n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(CC=1C(=CC=C(C=1)C=1C=C2C=CNC2=CC=1)F)CCN1CCCC1 HSKVFCUSNYYKBX-UHFFFAOYSA-N 0.000 description 1
- RGSJEKWEARVCBT-UHFFFAOYSA-N 4-fluoro-n-[[2-fluoro-5-(1h-pyrrolo[2,3-c]pyridin-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(CC=1C(=CC=C(C=1)C=1N=CC=2NC=CC=2C=1)F)CCN1CCCC1 RGSJEKWEARVCBT-UHFFFAOYSA-N 0.000 description 1
- UWLSAXUNLOGZKG-UHFFFAOYSA-N 4-fluoro-n-[[2-fluoro-5-(1h-pyrrolo[3,2-b]pyridin-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(CC=1C(=CC=C(C=1)C=1N=C2C=CNC2=CC=1)F)CCN1CCCC1 UWLSAXUNLOGZKG-UHFFFAOYSA-N 0.000 description 1
- MMLOGCJLVYBGMT-UHFFFAOYSA-N 4-fluoro-n-[[2-fluoro-5-(2-oxo-3h-1,3-benzoxazol-6-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CC(F)=CC=1)CC1=CC(C=2C=C3OC(=O)NC3=CC=2)=CC=C1F MMLOGCJLVYBGMT-UHFFFAOYSA-N 0.000 description 1
- VXJWXSCPMIQSMI-UHFFFAOYSA-N 4-fluoro-n-[[2-fluoro-5-(2-oxo-3h-1,3-benzoxazol-6-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(CC=1C(=CC=C(C=1)C=1C=C2OC(=O)NC2=CC=1)F)CCN1CCCC1 VXJWXSCPMIQSMI-UHFFFAOYSA-N 0.000 description 1
- XJNQGSDHNHZIJS-UHFFFAOYSA-N 4-fluoro-n-[[3-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CC(F)=CC=1)CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 XJNQGSDHNHZIJS-UHFFFAOYSA-N 0.000 description 1
- VRWQGLFKUQTKQC-UHFFFAOYSA-N 4-fluoro-n-[[4-fluoro-3-(1h-indol-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(CC=1C=C(C(F)=CC=1)C=1C=C2C=CNC2=CC=1)CCN1CCCC1 VRWQGLFKUQTKQC-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- PNEOKAGWIFEWNK-UHFFFAOYSA-N 5-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1h-indole Chemical compound C1CN(C)CCCN1CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 PNEOKAGWIFEWNK-UHFFFAOYSA-N 0.000 description 1
- IIZXKGJRAXFWTJ-UHFFFAOYSA-N 5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-indole Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 IIZXKGJRAXFWTJ-UHFFFAOYSA-N 0.000 description 1
- HAAPQNSHWVROTN-UHFFFAOYSA-N 5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-2h-benzotriazole Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C3N=NNC3=CC=2)=C1 HAAPQNSHWVROTN-UHFFFAOYSA-N 0.000 description 1
- CAKWHMWWQGQGJS-UHFFFAOYSA-N 5-[3-[[benzyl-[2-(dimethylamino)ethyl]amino]methyl]phenyl]-1,3-dihydrobenzimidazol-2-one;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3NC(=O)NC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 CAKWHMWWQGQGJS-UHFFFAOYSA-N 0.000 description 1
- POCWULSIEIASHP-UHFFFAOYSA-N 5-[4-fluoro-3-[(2-thiophen-2-ylpiperazin-1-yl)methyl]phenyl]-1h-indazole Chemical compound FC1=CC=C(C=2C=C3C=NNC3=CC=2)C=C1CN1CCNCC1C1=CC=CS1 POCWULSIEIASHP-UHFFFAOYSA-N 0.000 description 1
- CBGLMQWHEAXZDJ-UHFFFAOYSA-N 5-[4-fluoro-3-[(4-methyl-2-pyridin-4-ylpiperazin-1-yl)methyl]phenyl]-1h-indole Chemical compound C1N(C)CCN(CC=2C(=CC=C(C=2)C=2C=C3C=CNC3=CC=2)F)C1C1=CC=NC=C1 CBGLMQWHEAXZDJ-UHFFFAOYSA-N 0.000 description 1
- GJHBOZUUYVMRNH-UHFFFAOYSA-N 5-[4-fluoro-3-[[2-(4-fluorophenyl)piperazin-1-yl]methyl]phenyl]-1h-indazole Chemical compound C1=CC(F)=CC=C1C1N(CC=2C(=CC=C(C=2)C=2C=C3C=NNC3=CC=2)F)CCNC1 GJHBOZUUYVMRNH-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- REPHVNGRWIFVMJ-UHFFFAOYSA-N 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C3OC(=O)NC3=CC=2)=C1 REPHVNGRWIFVMJ-UHFFFAOYSA-N 0.000 description 1
- CLAHVIWPABLYNF-UHFFFAOYSA-N 6-[3-[[benzyl-[2-(dimethylamino)ethyl]amino]methyl]phenyl]-3-methyl-1h-quinazoline-2,4-dione;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3C(=O)N(C)C(=O)NC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 CLAHVIWPABLYNF-UHFFFAOYSA-N 0.000 description 1
- BYNVFXLKWAWEFK-UHFFFAOYSA-N 6-[4-fluoro-3-[(2-thiophen-2-ylpiperazin-1-yl)methyl]phenyl]-3h-1,3-benzoxazol-2-one Chemical compound FC1=CC=C(C=2C=C3OC(=O)NC3=CC=2)C=C1CN1CCNCC1C1=CC=CS1 BYNVFXLKWAWEFK-UHFFFAOYSA-N 0.000 description 1
- QCPQMQBXFGUSQZ-NRFANRHFSA-N 6-[5-[[(2r)-2-(4-fluorophenyl)-4-methylpiperazin-1-yl]methyl]furan-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1([C@H]2N(CC=3OC=C(C=3)C=3C=C4OC(=O)NC4=CC=3)CCN(C2)C)=CC=C(F)C=C1 QCPQMQBXFGUSQZ-NRFANRHFSA-N 0.000 description 1
- IKFVERNEDYZIRR-UHFFFAOYSA-N 6-[5-[[(4-fluorophenyl)methyl-(1-methylpiperidin-4-yl)amino]methyl]furan-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCC1N(CC=1C=CC(F)=CC=1)CC1=CC(C=2C=C3OC(=O)NC3=CC=2)=CO1 IKFVERNEDYZIRR-UHFFFAOYSA-N 0.000 description 1
- DXBFXQJNQZFORV-UHFFFAOYSA-N 6-[5-[[2-(dimethylamino)ethyl-[(4-fluorophenyl)methyl]amino]methyl]furan-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C=1C(C=2C=C3OC(=O)NC3=CC=2)=COC=1CN(CCN(C)C)CC1=CC=C(F)C=C1 DXBFXQJNQZFORV-UHFFFAOYSA-N 0.000 description 1
- HBINRFRIDMACKS-UHFFFAOYSA-N 6-[5-[[2-(dimethylamino)ethyl-[(4-fluorophenyl)methyl]amino]methyl]pyridin-3-yl]-3h-1,3-benzoxazol-2-one Chemical compound C=1N=CC(C=2C=C3OC(=O)NC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=C(F)C=C1 HBINRFRIDMACKS-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150010783 Aard gene Proteins 0.000 description 1
- 206010001296 Adjustment disorder with anxiety Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- NZGZNNPUIKUMJG-UHFFFAOYSA-N N-[[5-(2H-benzotriazol-5-yl)-2-fluorophenyl]methyl]-N-(2-pyrrolidin-1-ylethyl)thiophene-2-carboxamide hydrochloride Chemical compound Cl.FC1=CC=C(C=2C=C3N=NNC3=CC=2)C=C1CN(C(=O)C=1SC=CC=1)CCN1CCCC1 NZGZNNPUIKUMJG-UHFFFAOYSA-N 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- GLLZJALTEROMBK-UHFFFAOYSA-N OC(=O)C(F)(F)F.N#Cc1c[nH]c2ccccc12 Chemical compound OC(=O)C(F)(F)F.N#Cc1c[nH]c2ccccc12 GLLZJALTEROMBK-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010067775 Upper airway obstruction Diseases 0.000 description 1
- 206010063968 Upper airway resistance syndrome Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- UNRBEYYLYRXYCG-ZETCQYMHSA-N [(2s)-1-ethylpyrrolidin-2-yl]methanamine Chemical compound CCN1CCC[C@H]1CN UNRBEYYLYRXYCG-ZETCQYMHSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- OMNCZRGZYURYEO-UHFFFAOYSA-N acetic acid;5-[4-fluoro-3-[(2-thiophen-2-ylpiperazin-1-yl)methyl]phenyl]-1h-indazole Chemical compound CC(O)=O.FC1=CC=C(C=2C=C3C=NNC3=CC=2)C=C1CN1CCNCC1C1=CC=CS1 OMNCZRGZYURYEO-UHFFFAOYSA-N 0.000 description 1
- SJFFDJGHUDCLNC-UHFFFAOYSA-N acetic acid;5-[4-fluoro-3-[(4-methyl-2-pyridin-2-ylpiperazin-1-yl)methyl]phenyl]-1h-indole Chemical compound CC(O)=O.C1N(C)CCN(CC=2C(=CC=C(C=2)C=2C=C3C=CNC3=CC=2)F)C1C1=CC=CC=N1 SJFFDJGHUDCLNC-UHFFFAOYSA-N 0.000 description 1
- ZATHGVHUMFFOPY-UHFFFAOYSA-N acetic acid;5-[4-fluoro-3-[(4-methyl-2-pyridin-3-ylpiperazin-1-yl)methyl]phenyl]-1h-indole Chemical compound CC(O)=O.C1N(C)CCN(CC=2C(=CC=C(C=2)C=2C=C3C=CNC3=CC=2)F)C1C1=CC=CN=C1 ZATHGVHUMFFOPY-UHFFFAOYSA-N 0.000 description 1
- FYQHOMRRLAEDKH-VZYDHVRKSA-N acetic acid;5-[4-fluoro-3-[[(2r)-4-methyl-2-thiophen-2-ylpiperazin-1-yl]methyl]phenyl]-1h-indazole Chemical compound CC(O)=O.C1([C@@H]2N(CC=3C(=CC=C(C=3)C=3C=C4C=NNC4=CC=3)F)CCN(C2)C)=CC=CS1 FYQHOMRRLAEDKH-VZYDHVRKSA-N 0.000 description 1
- JYVSZCNTYXUUGH-UHFFFAOYSA-N acetic acid;benzamide Chemical compound CC(O)=O.NC(=O)C1=CC=CC=C1 JYVSZCNTYXUUGH-UHFFFAOYSA-N 0.000 description 1
- WHSAOBZVNVTBQH-UHFFFAOYSA-N acetic acid;n'-[(4-fluorophenyl)methyl]-n'-[[5-(1h-indazol-5-yl)pyridin-3-yl]methyl]-n,n-dimethylethane-1,2-diamine Chemical compound CC(O)=O.C=1N=CC(C=2C=C3C=NNC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=C(F)C=C1 WHSAOBZVNVTBQH-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PXWLUICTRPHECG-UHFFFAOYSA-N azane;trihydrochloride Chemical compound N.Cl.Cl.Cl PXWLUICTRPHECG-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BMBANPOHPFKVTA-UHFFFAOYSA-N benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)C1=CC=CC=C1 BMBANPOHPFKVTA-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000014486 central sleep apnea syndrome Diseases 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- MSWIFFGHKBTPMY-VFUQPONKSA-L magnesium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O MSWIFFGHKBTPMY-VFUQPONKSA-L 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- NORFKNIONUICLG-UHFFFAOYSA-N n'-[[2-fluoro-5-(1h-indazol-5-yl)phenyl]methyl]-n'-[(4-fluorophenyl)methyl]-n-methylethane-1,2-diamine Chemical compound C=1C(C=2C=C3C=NNC3=CC=2)=CC=C(F)C=1CN(CCNC)CC1=CC=C(F)C=C1 NORFKNIONUICLG-UHFFFAOYSA-N 0.000 description 1
- XTKIJZIFRJNQDD-UHFFFAOYSA-N n'-[[3-(2h-benzotriazol-5-yl)phenyl]methyl]-n'-benzyl-n,n-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3N=NNC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 XTKIJZIFRJNQDD-UHFFFAOYSA-N 0.000 description 1
- DPKOENODKZISQV-UHFFFAOYSA-N n'-[[3-(2h-benzotriazol-5-yl)phenyl]methyl]-n'-benzyl-n,n-dimethylpropane-1,3-diamine Chemical compound C=1C=CC(C=2C=C3N=NNC3=CC=2)=CC=1CN(CCCN(C)C)CC1=CC=CC=C1 DPKOENODKZISQV-UHFFFAOYSA-N 0.000 description 1
- VPEYZBPHUGTNEJ-UHFFFAOYSA-N n'-[[3-(3h-benzimidazol-5-yl)phenyl]methyl]-n'-benzyl-n,n-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3N=CNC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 VPEYZBPHUGTNEJ-UHFFFAOYSA-N 0.000 description 1
- NAYKHKCDIGPIHB-UHFFFAOYSA-N n'-[[3-(3h-benzimidazol-5-yl)phenyl]methyl]-n'-benzyl-n,n-dimethylpropane-1,3-diamine;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3N=CNC3=CC=2)=CC=1CN(CCCN(C)C)CC1=CC=CC=C1 NAYKHKCDIGPIHB-UHFFFAOYSA-N 0.000 description 1
- CLRXDNKIZRKYCU-UHFFFAOYSA-N n'-benzyl-n'-[[3-(1h-indazol-5-yl)phenyl]methyl]-n,n-dimethylethane-1,2-diamine;hydrochloride Chemical compound Cl.C=1C=CC(C=2C=C3C=NNC3=CC=2)=CC=1CN(CCN(C)C)CC1=CC=CC=C1 CLRXDNKIZRKYCU-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MFQZPMOHMWBCSP-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-ylmethyl)-4-fluoro-n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(F)=CC=C1C(=O)N(CC12CCN(CC1)CC2)CC1=CC(C=2C=C3C=CNC3=CC=2)=CC=C1F MFQZPMOHMWBCSP-UHFFFAOYSA-N 0.000 description 1
- KWTRAOYWRQCOTR-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-4-fluoro-n-[[2-fluoro-5-(1-tritylbenzotriazol-5-yl)phenyl]methyl]benzamide Chemical compound CCN1CCCC1CN(C(=O)C=1C=CC(F)=CC=1)CC1=CC(C=2C=C3N=NN(C3=CC=2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1F KWTRAOYWRQCOTR-UHFFFAOYSA-N 0.000 description 1
- BPOOZSRHPOZVSF-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-4-fluoro-n-[[2-fluoro-5-(2-oxo-3h-1,3-benzoxazol-6-yl)phenyl]methyl]benzamide Chemical compound CCN1CCCC1CN(C(=O)C=1C=CC(F)=CC=1)CC1=CC(C=2C=C3OC(=O)NC3=CC=2)=CC=C1F BPOOZSRHPOZVSF-UHFFFAOYSA-N 0.000 description 1
- ZOMCDVCZLMXNCC-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-fluoro-n-[[2-fluoro-5-(2-oxo-3h-1,3-benzoxazol-6-yl)phenyl]methyl]benzamide Chemical compound C=1C(C=2C=C3OC(=O)NC3=CC=2)=CC=C(F)C=1CN(CCN(C)C)C(=O)C1=CC=C(F)C=C1 ZOMCDVCZLMXNCC-UHFFFAOYSA-N 0.000 description 1
- NSJJGGIMSVSOJR-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]thiophene-2-carboxamide Chemical compound C=1C(C=2C=C3C=CNC3=CC=2)=CC=C(F)C=1CN(CCN(C)C)C(=O)C1=CC=CS1 NSJJGGIMSVSOJR-UHFFFAOYSA-N 0.000 description 1
- UJJWRSYPYQWWFJ-UHFFFAOYSA-N n-[[2-chloro-5-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)pyridine-4-carboxamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CN=CC=1)CC1=CC(C=2C=C3C=CNC3=CC=2)=CC=C1Cl UJJWRSYPYQWWFJ-UHFFFAOYSA-N 0.000 description 1
- DPHQJISNFIGVKI-UHFFFAOYSA-N n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)-4-(trifluoromethoxy)benzamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CC(OC(F)(F)F)=CC=1)CC1=CC(C=2C=C3C=CNC3=CC=2)=CC=C1F DPHQJISNFIGVKI-UHFFFAOYSA-N 0.000 description 1
- DPFXEHRVNPYVOK-UHFFFAOYSA-N n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)pyridine-4-carboxamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CN=CC=1)CC1=CC(C=2C=C3C=CNC3=CC=2)=CC=C1F DPFXEHRVNPYVOK-UHFFFAOYSA-N 0.000 description 1
- YPMFOVMXSKGTSS-UHFFFAOYSA-N n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)thiophene-2-carboxamide Chemical compound C1CN(C)CCC1N(C(=O)C=1SC=CC=1)CC1=CC(C=2C=C3C=CNC3=CC=2)=CC=C1F YPMFOVMXSKGTSS-UHFFFAOYSA-N 0.000 description 1
- GHKZCYUPGIOECR-UHFFFAOYSA-N n-[[2-fluoro-5-(1h-indol-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)pyridine-4-carboxamide Chemical compound FC1=CC=C(C=2C=C3C=CNC3=CC=2)C=C1CN(C(=O)C=1C=CN=CC=1)CCN1CCCC1 GHKZCYUPGIOECR-UHFFFAOYSA-N 0.000 description 1
- UHRYIQCHOOCYHR-UHFFFAOYSA-N n-[[3-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)pyridine-4-carboxamide Chemical compound C1CN(C)CCC1N(C(=O)C=1C=CN=CC=1)CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 UHRYIQCHOOCYHR-UHFFFAOYSA-N 0.000 description 1
- JEPATVHORFCQTI-UHFFFAOYSA-N n-[[3-(1h-indol-5-yl)phenyl]methyl]-n-(1-methylpiperidin-4-yl)thiophene-2-carboxamide Chemical compound C1CN(C)CCC1N(C(=O)C=1SC=CC=1)CC1=CC=CC(C=2C=C3C=CNC3=CC=2)=C1 JEPATVHORFCQTI-UHFFFAOYSA-N 0.000 description 1
- WOGYNPXAPRCMRZ-UHFFFAOYSA-N n-[[3-(1h-indol-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)N(CC=1C=C(C=CC=1)C=1C=C2C=CNC2=CC=1)CCN1CCCC1 WOGYNPXAPRCMRZ-UHFFFAOYSA-N 0.000 description 1
- DYFGGUFRZROJMX-UHFFFAOYSA-N n-[[3-(1h-indol-5-yl)phenyl]methyl]-n-(3-pyrrolidin-1-ylpropyl)pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)N(CC=1C=C(C=CC=1)C=1C=C2C=CNC2=CC=1)CCCN1CCCC1 DYFGGUFRZROJMX-UHFFFAOYSA-N 0.000 description 1
- PAPQFLQECSCDRM-UHFFFAOYSA-N n-[[3-(2h-benzotriazol-5-yl)phenyl]methyl]-4-fluoro-n-(2-pyrrolidin-1-ylethyl)benzamide;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=C2N=NNC2=CC=1)CCN1CCCC1 PAPQFLQECSCDRM-UHFFFAOYSA-N 0.000 description 1
- OVCJQDAKFFGOCX-UHFFFAOYSA-N n-[[4-(1h-indol-5-yl)furan-2-yl]methyl]-n-(3-pyrrolidin-1-ylpropyl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N(CC=1OC=C(C=1)C=1C=C2C=CNC2=CC=1)CCCN1CCCC1 OVCJQDAKFFGOCX-UHFFFAOYSA-N 0.000 description 1
- CWVWGQFRGMHKAB-UHFFFAOYSA-N n-[[4-(1h-indol-5-yl)furan-2-yl]methyl]-n-(3-pyrrolidin-1-ylpropyl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)N(CC=1OC=C(C=1)C=1C=C2C=CNC2=CC=1)CCCN1CCCC1 CWVWGQFRGMHKAB-UHFFFAOYSA-N 0.000 description 1
- KPVUJWOELRRDSC-UHFFFAOYSA-N n-[[4-(1h-indol-5-yl)thiophen-2-yl]methyl]-n-(2-pyrrolidin-1-ylethyl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)N(CC=1SC=C(C=1)C=1C=C2C=CNC2=CC=1)CCN1CCCC1 KPVUJWOELRRDSC-UHFFFAOYSA-N 0.000 description 1
- PARQLKCEFTVVPF-UHFFFAOYSA-N n-[[4-fluoro-3-(1h-indol-5-yl)phenyl]methyl]-n-(2-pyrrolidin-1-ylethyl)pyridine-4-carboxamide Chemical compound C1=C(C=2C=C3C=CNC3=CC=2)C(F)=CC=C1CN(C(=O)C=1C=CN=CC=1)CCN1CCCC1 PARQLKCEFTVVPF-UHFFFAOYSA-N 0.000 description 1
- UDFOJJRJSZPOPQ-UHFFFAOYSA-N n-[[4-fluoro-3-(1h-indol-5-yl)phenyl]methyl]-n-(3-pyrrolidin-1-ylpropyl)pyridine-4-carboxamide Chemical compound C1=C(C=2C=C3C=CNC3=CC=2)C(F)=CC=C1CN(C(=O)C=1C=CN=CC=1)CCCN1CCCC1 UDFOJJRJSZPOPQ-UHFFFAOYSA-N 0.000 description 1
- BPIPIBXGOHQVAI-UHFFFAOYSA-N n-[[5-(2,3-dihydro-1h-indol-5-yl)-2-fluorophenyl]methyl]-n-[2-(dimethylamino)ethyl]-4-fluorobenzamide Chemical compound C=1C(C=2C=C3CCNC3=CC=2)=CC=C(F)C=1CN(CCN(C)C)C(=O)C1=CC=C(F)C=C1 BPIPIBXGOHQVAI-UHFFFAOYSA-N 0.000 description 1
- KRBDRYLXOICLQH-UHFFFAOYSA-N n-[[5-(2h-benzotriazol-5-yl)-2-fluorophenyl]methyl]-4-fluoro-n-(1-propan-2-ylpiperidin-4-yl)benzamide Chemical compound C1CN(C(C)C)CCC1N(C(=O)C=1C=CC(F)=CC=1)CC1=CC(C=2C=C3N=NNC3=CC=2)=CC=C1F KRBDRYLXOICLQH-UHFFFAOYSA-N 0.000 description 1
- IFPYUMUOSRWJPM-UHFFFAOYSA-N n-[[5-(2h-benzotriazol-5-yl)-2-fluorophenyl]methyl]-4-fluoro-n-piperidin-4-ylbenzamide Chemical compound C1=CC(F)=CC=C1C(=O)N(C1CCNCC1)CC1=CC(C=2C=C3N=NNC3=CC=2)=CC=C1F IFPYUMUOSRWJPM-UHFFFAOYSA-N 0.000 description 1
- SFIIUXLAGNDLGX-UHFFFAOYSA-N n-[[5-(2h-benzotriazol-5-yl)-2-fluorophenyl]methyl]-n-(thiophen-2-ylmethyl)piperidin-4-amine Chemical compound FC1=CC=C(C=2C=C3N=NNC3=CC=2)C=C1CN(C1CCNCC1)CC1=CC=CS1 SFIIUXLAGNDLGX-UHFFFAOYSA-N 0.000 description 1
- MWBKYWAJVNXSPQ-UHFFFAOYSA-N n-[[5-(2h-benzotriazol-5-yl)-2-fluorophenyl]methyl]-n-[(4-fluorophenyl)methyl]piperidin-4-amine Chemical compound C1=CC(F)=CC=C1CN(C1CCNCC1)CC1=CC(C=2C=C3N=NNC3=CC=2)=CC=C1F MWBKYWAJVNXSPQ-UHFFFAOYSA-N 0.000 description 1
- LLSJAFHDYCTFCM-UHFFFAOYSA-N n-benzyl-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNCC1=CC=CC=C1 LLSJAFHDYCTFCM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000037053 non-rapid eye movement Effects 0.000 description 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 1
- JUSIWJONLKBPDU-UHFFFAOYSA-N pyridazine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NN=C1 JUSIWJONLKBPDU-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- QXDZFQJKFNXQTL-UHFFFAOYSA-N tert-butyl 2-(4-fluorophenyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1C1=CC=C(F)C=C1 QXDZFQJKFNXQTL-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70965505P | 2005-08-19 | 2005-08-19 | |
| US60/709,655 | 2005-08-19 | ||
| PCT/US2006/032027 WO2007024600A2 (en) | 2005-08-19 | 2006-08-16 | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006283703A1 true AU2006283703A1 (en) | 2007-03-01 |
Family
ID=37772166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006283703A Abandoned AU2006283703A1 (en) | 2005-08-19 | 2006-08-16 | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7618650B2 (enExample) |
| EP (1) | EP1928442B1 (enExample) |
| JP (1) | JP2009504761A (enExample) |
| KR (1) | KR20080038416A (enExample) |
| CN (1) | CN101242819A (enExample) |
| AR (1) | AR055609A1 (enExample) |
| AT (1) | ATE447400T1 (enExample) |
| AU (1) | AU2006283703A1 (enExample) |
| BR (1) | BRPI0614943A2 (enExample) |
| CA (1) | CA2617980A1 (enExample) |
| DE (1) | DE602006010219D1 (enExample) |
| ES (1) | ES2336142T3 (enExample) |
| MX (1) | MX2008001778A (enExample) |
| RU (1) | RU2008110498A (enExample) |
| SG (1) | SG140147A1 (enExample) |
| TW (1) | TW200815009A (enExample) |
| WO (1) | WO2007024600A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| AU2005338350A1 (en) * | 2005-11-18 | 2007-05-24 | Solapharm, Inc. | Segmented pharmaceutical dosage forms |
| WO2010045190A1 (en) | 2008-10-15 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
| EP2340243B1 (en) | 2008-10-17 | 2014-10-08 | Boehringer Ingelheim International GmbH | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| CN102018681A (zh) * | 2010-12-10 | 2011-04-20 | 荣港生技医药科技（北京）有限公司 | 一种美乐托宁缓释剂、其制备方法及其应用 |
| US20130060052A1 (en) * | 2011-01-17 | 2013-03-07 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| SI2970132T1 (sl) | 2013-03-14 | 2021-02-26 | Epizyme, Inc. | Inhibitorji argininmetiltransferaze in njihove uporabe |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20250282753A1 (en) * | 2022-04-27 | 2025-09-11 | Atom Bioscience America Corporation | Compounds useful for reducing uric acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69739733D1 (de) * | 1996-10-21 | 2010-02-25 | Neurosearch As | 1-phenyl-benzimidazolverbindungen und ihre verwendung als modulatoren des gaba-a-rezeptors |
| US20040258750A1 (en) * | 1999-06-28 | 2004-12-23 | Gerard Alaux | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| DK1292304T3 (da) * | 2000-04-24 | 2005-12-19 | Teva Pharma | Zolpidem Hemitartrat |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
-
2006
- 2006-08-16 MX MX2008001778A patent/MX2008001778A/es not_active Application Discontinuation
- 2006-08-16 AU AU2006283703A patent/AU2006283703A1/en not_active Abandoned
- 2006-08-16 CA CA002617980A patent/CA2617980A1/en not_active Abandoned
- 2006-08-16 BR BRPI0614943-0A patent/BRPI0614943A2/pt not_active IP Right Cessation
- 2006-08-16 KR KR1020087006619A patent/KR20080038416A/ko not_active Withdrawn
- 2006-08-16 SG SG200801326A patent/SG140147A1/en unknown
- 2006-08-16 DE DE602006010219T patent/DE602006010219D1/de active Active
- 2006-08-16 WO PCT/US2006/032027 patent/WO2007024600A2/en not_active Ceased
- 2006-08-16 CN CNA2006800296536A patent/CN101242819A/zh active Pending
- 2006-08-16 RU RU2008110498/04A patent/RU2008110498A/ru not_active Application Discontinuation
- 2006-08-16 EP EP06789813A patent/EP1928442B1/en active Active
- 2006-08-16 JP JP2008527115A patent/JP2009504761A/ja active Pending
- 2006-08-16 ES ES06789813T patent/ES2336142T3/es active Active
- 2006-08-16 AT AT06789813T patent/ATE447400T1/de not_active IP Right Cessation
- 2006-08-17 AR ARP060103594A patent/AR055609A1/es unknown
- 2006-08-18 TW TW095130323A patent/TW200815009A/zh unknown
-
2008
- 2008-02-06 US US12/027,022 patent/US7618650B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007024600A2 (en) | 2007-03-01 |
| US7618650B2 (en) | 2009-11-17 |
| ES2336142T3 (es) | 2010-04-08 |
| ATE447400T1 (de) | 2009-11-15 |
| RU2008110498A (ru) | 2009-09-27 |
| US20080138413A1 (en) | 2008-06-12 |
| CA2617980A1 (en) | 2007-03-01 |
| EP1928442A2 (en) | 2008-06-11 |
| SG140147A1 (en) | 2008-03-28 |
| KR20080038416A (ko) | 2008-05-06 |
| EP1928442B1 (en) | 2009-11-04 |
| TW200815009A (en) | 2008-04-01 |
| WO2007024600A3 (en) | 2007-05-24 |
| BRPI0614943A2 (pt) | 2011-04-26 |
| DE602006010219D1 (de) | 2009-12-17 |
| CN101242819A (zh) | 2008-08-13 |
| MX2008001778A (es) | 2008-04-07 |
| JP2009504761A (ja) | 2009-02-05 |
| AR055609A1 (es) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7625889B2 (en) | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | |
| US7618650B2 (en) | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof | |
| TWI833773B (zh) | 化合物 | |
| EP2455370A1 (en) | Pharmaceutical product containing lactam or benzene sulfonamide compound | |
| RU2528406C2 (ru) | Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в | |
| HK1254853A1 (zh) | 用於治疗睡眠相关的呼吸病症的作为task-1和task-2通道阻断剂的2-苯基-3-(哌嗪子基甲基)咪唑并[1，2-a]吡啶衍生物 | |
| TW200808310A (en) | Amide derivative or salt thereof | |
| CA3031136A1 (en) | Substituted imidazo[1,2-a]pyridin-3-yl compounds and their use for the treatment and/or prevention of respiratory disorders | |
| CN119343343A (zh) | 杂环glp-1激动剂 | |
| EA006604B1 (ru) | Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
| CN105829301A (zh) | 作为离子通道调节剂的稠合杂环化合物 | |
| JP5101639B2 (ja) | アミド誘導体及びそれを含有する医薬組成物 | |
| CN111542529B (zh) | 对蛋白激酶具有抑制活性的噻吩并[3,2-d]嘧啶化合物 | |
| JP7558266B2 (ja) | プロスタグランジンｅｐ４受容体アンタゴニスト化合物 | |
| TR201807174T4 (tr) | Kırılgan x sendromu, parkinson veya reflü hastalığının tedavisinde faydalı diazepinon türevleri. | |
| HK1121673A (en) | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof | |
| JP5156806B2 (ja) | アミド誘導体からなる医薬 | |
| US20080139615A1 (en) | Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof | |
| CN117616022A (zh) | 晶形 | |
| HK1113789A (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |